A licensing deal worth potentially up to $1.2 billion with Sanofi SA has breathed new life into Novavax Inc., which has struggled to compete in the COVID-19 space with powerhouses Pfizer Inc. and Moderna Inc. Read More
Macrogenics Inc. CEO Scott Koenig said his firm is “on the right pathway” with vobramitamab duocarmazine (vobra duo), previously known as MGC-018, in metastatic castration-resistant prostate cancer. Wall Street proved less than thrilled, and shares of the Rockville, Md.-based firm (NASDAQ:MGNX) closed May 10 at $3.31, down $11.36, or 77%, after Macrogenics disclosed phase II results from the Tamarack study with vobra duo. Read More
Innovent Biologics Inc.’s glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor dual agonist, mazdutide, met the primary endpoint of superiority in a head-to-head phase III trial in Chinese patients with type 2 diabetes compared to Eli Lilly and Co.’s GLP-1, dulaglutide, for glycemic control. Read More
The BioWorld Infectious Disease Index (BIDI) has continued to decline in the first four months of 2024, finishing April with a year-to-date decrease of 25.12%. BIDI trailed both the Nasdaq Biotechnology Index, which saw a 4.76% downturn by April’s end, and the Dow Jones Industrial Average, which closed the month with a 0.34% increase for the year. In 2023, BIDI ended the year with a 43.48% decline, preceded by an 83.57% drop in 2022. Read More
From glaucoma to Stargardt disease, age-related macular degeneration (AMD) to retinitis pigmentosa, or a corneal transplant to Bietti’s crystalline dystrophy, the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) is working to bring some light to patients with age and congenital diseases that affect vision. From May 7-11, 2024, thousands of scientists are gathering in Baltimore to show their advances against the challenges of delivering genes and cells to the correct place, avoiding immunogenicity and improving diseases. Read More
The U.K.’s world-first subscription model for antimicrobials is to be expanded following a successful pilot scheme in which companies are being paid a fixed annual fee for their drugs, regardless of the volume dispensed. Read More
SN Bioscience Co. Ltd., headquartered in Seongnam-si, Gyeonggi-do’s second Pangyo Valley, gained U.S. FDA fast track designation for SNB-101 (SN-38), its new polymer nanoparticle cancer drug candidate for small-cell lung cancer. Read More
In April, the value of biopharma deals climbed to $15.28 billion, increasing 84% from March’s $8.29 billion and also up from February’s $7.76 billion, though there was a decline from January’s $27.9 billion. This amounts to a monthly average of $14.86 billion in deal value for 2024, compared to the $18.14 billion monthly average in 2023. Meanwhile, the value of biopharma M&As dipped to $1.33 billion for the month, marking the lowest figure in nearly a year. Read More
BioWorld Managing Editor Karen Carey joins the podcast to talk about the numbers from the first quarter of 2024, along with a look back at some 2023 deals and indicators that signal better times are on the way. Financings for the quarter were better than expected, sporting some of the best numbers of the past 13 years. It’s part of a larger trend, Carey says, of investors being a lot pickier about where they put their money and demanding better data. The result is a strengthened market and a better outlook. Read More
The recent cyberattack on Change Healthcare, a part of the Unitedhealth Group, crippled reimbursement claims processing for thousands of providers for several weeks and potentially exposed troves of patient data. Congressional committees are investigating the attack, its scope, and Unitedhealth’s response. Please take a few minutes to fill out this short survey to help BioWorld understand how your company is responding to these threats. You can click through to the questions here. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Annovis, Apnimed, Cytomx, Fate, Freeline, Innovent, Merck & Co., Oculis, Onechain, Tscan. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Calico, Coherus, Derm-Biome, Formosa, Phanes, Roche, Tabuk. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Can-Fite, Inhibikase, Oncolytics. Read More
